BDRX (Biodexa Pharmaceuticals) Current Deferred Revenue: $0.76 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BDRX Biodexa Pharmaceuticals PLC BDRX
45 GF Score
Price $1.31
View Full Analysis

What is Biodexa Pharmaceuticals Current Deferred Revenue?

Biodexa Pharmaceuticals BDRX -9.59% 45 Current Deferred Revenue is $0.76 Mil as of Dec. 2025. GuruFocus rates BDRX with a GF Score™ of 45/100.

Current Deferred Revenue represents collections of cash or other assets related to revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. It can be either current or non-current item. Also called unearned revenue.

Biodexa Pharmaceuticals's current deferred revenue for the quarter that ended in Dec. 2025 was $0.76 Mil.

Biodexa Pharmaceuticals Current Deferred Revenue Related Terms

Biodexa Pharmaceuticals Current Deferred Revenue Historical Data

* Premium members only.

The historical data trend for Biodexa Pharmaceuticals's Current Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biodexa Pharmaceuticals Current Deferred Revenue Chart

Biodexa Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Current Deferred Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.24 0.00 1.86 0.76

Biodexa Pharmaceuticals Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Current Deferred Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 1.86 0.00 0.76
BDRX
45GF Score
Biodexa Pharmaceuticals PLC BDRX
Current Deferred Revenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Current Deferred Revenue of $0.76 Mil mean?
Biodexa Pharmaceuticals (BDRX) has a Current Deferred Revenue of $0.76 Mil as of Dec. 2025. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on Biodexa Pharmaceuticals and its competitors.
Is Biodexa Pharmaceuticals' Current Deferred Revenue too high?
Biodexa Pharmaceuticals' current Current Deferred Revenue is $0.76 Mil. Overall, Biodexa Pharmaceuticals has a GF Score™ of 45/100, reflecting its overall financial health beyond just this single metric.
How does Biodexa Pharmaceuticals' Current Deferred Revenue compare to VIVS and MTNB?
Biodexa Pharmaceuticals' Current Deferred Revenue of $0.76 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Deferred Revenue for a Biotechnology company?
A good Current Deferred Revenue depends on the Biotechnology industry context. However, Current Deferred Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Deferred Revenue mean?
A high Current Deferred Revenue can signal that a stock is expensive relative to its fundamentals. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on Biodexa Pharmaceuticals and its competitors. Biodexa Pharmaceuticals's current Current Deferred Revenue is $0.76 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biodexa Pharmaceuticals stock overvalued right now?
Biodexa Pharmaceuticals (BDRX) has a current Current Deferred Revenue of $0.76 Mil. The current Current Deferred Revenue is $0.76 Mil. Biodexa Pharmaceuticals' overall GF Score™ is 45/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Deferred Revenue calculated?
Current Deferred Revenue is calculated from a company's financial statements. For Biodexa Pharmaceuticals (BDRX), the current Current Deferred Revenue is $0.76 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Biodexa Pharmaceuticals Business Description

Address 1 Caspian Point, Caspian Way, Cardiff, GBR, CF10 4DQ
Biodexa Pharmaceuticals PLC is a clinical-stage biopharmaceutical company focused on developing a pipeline of products to treat diseases that have unmet medical needs. These include familial adenomatous polyposis (FAP), non-muscle invasive bladder cancer (NMIBC), type 1 diabetes (T1D), and rare or orphan brain cancers.
45GF Score

Get the complete analysis for BDRX

Current Deferred Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.31
Price